The firm is pursuing regulatory clearance for multiple tests and is targeting growth in an attractive CLIA market, a move that will require new hires.
The research may lay the groundwork for a noninvasive test for GI or other types of cancer without prior knowledge of which organ is affected.
The increased revenue was driven by growth in the firm's commercial clinical business.
New product revenues more than doubled year over year, while infectious disease test revenues grew 35 percent.
The license was issued to the firm's distribution partner, Xcelris Labs, and Epistem intends to begin placing its Genedrive molecular platforms in the coming months.
In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.
The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.
The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.
An Australian study of personalized medicine has run into problems as it recruits patients.